| Literature DB >> 26932466 |
Magnus Trägårdh1,2, Michael J Chappell3, Andrea Ahnmark4, Daniel Lindén4, Neil D Evans3, Peter Gennemark5.
Abstract
Input estimation is employed in cases where it is desirable to recover the form of an input function which cannot be directly observed and for which there is no model for the generating process. In pharmacokinetic and pharmacodynamic modelling, input estimation in linear systems (deconvolution) is well established, while the nonlinear case is largely unexplored. In this paper, a rigorous definition of the input-estimation problem is given, and the choices involved in terms of modelling assumptions and estimation algorithms are discussed. In particular, the paper covers Maximum a Posteriori estimates using techniques from optimal control theory, and full Bayesian estimation using Markov Chain Monte Carlo (MCMC) approaches. These techniques are implemented using the optimisation software CasADi, and applied to two example problems: one where the oral absorption rate and bioavailability of the drug eflornithine are estimated using pharmacokinetic data from rats, and one where energy intake is estimated from body-mass measurements of mice exposed to monoclonal antibodies targeting the fibroblast growth factor receptor (FGFR) 1c. The results from the analysis are used to highlight the strengths and weaknesses of the methods used when applied to sparsely sampled data. The presented methods for optimal control are fast and robust, and can be recommended for use in drug discovery. The MCMC-based methods can have long running times and require more expertise from the user. The rigorous definition together with the illustrative examples and suggestions for software serve as a highly promising starting point for application of input-estimation methods to problems in drug discovery.Entities:
Keywords: Deconvolution; Input estimation; Markov Chain Monte Carlo method; Nonlinear dynamic systems; Optimal control
Mesh:
Substances:
Year: 2016 PMID: 26932466 PMCID: PMC4791487 DOI: 10.1007/s10928-016-9467-z
Source DB: PubMed Journal: J Pharmacokinet Pharmacodyn ISSN: 1567-567X Impact factor: 2.745
Fig. 1The input estimation problem: given measurements and known system dynamics, estimate the input function without modelling its generating process
Fig. 2Three-compartment model for Case Study 1. The aim is to estimate the function u(t) given measurements of
Fig. 3Estimated absorption rates, predicted plasma concentrations, and plasma concentration measurements for low and high doses with both log- and linear-scale models in Case Study 1. All estimates are calculated using the mid value for the regularisation parameter. The shaded regions are 95 % credible intervals. MAP estimates were obtained with single shooting, and mean and credible interval estimates were obtained with MCMC
Fig. 4Example L-curve obtained for the low-dose dataset in Case Study 1. Three values for were selected to be used in the subsequent analysis
Fig. 5Kernel density estimate of the posterior of the oral bioavailabilities in Case Study 1. The solid line represents the mean, and the dashed lines show the 95 % credible interval
Fig. 6Measured and estimated energy intake and body mass for all datasets in Case Study 2. The body-mass measurements (circles) were used for estimation, while the energy-intake measurements (triangles) are not known to the estimation algorithm and are plotted for comparison with the estimates. The shaded regions are 95 % credible intervals
Fig. 7Representative MCMC traces for a parameter (R1c mAb opt1, 10 mg/kg, coefficient 6). It can be clearly seen that SMMALA traces explore the parameter space more efficiently
Running time and ESS for the time-series in Case Study 2
| Dose group | Method | Number of samples | Time (s) | Median ESS | Median ESS (s) |
|---|---|---|---|---|---|
| Vehicle | SMMALA | 5000 | 151.1 | 940.8 | 6.2 |
| R1c mAb opt1 (0.3 mg/kg) | SMMALA | 5000 | 172.6 | 685.5 | 4.0 |
| R1c mAb opt1 (3 mg/kg) | SMMALA | 5000 | 179.1 | 601.6 | 3.4 |
| R1c mAb opt1 (10 mg/kg) | SMMALA | 5000 | 172.6 | 694.6 | 4.0 |
| R1c mAb opt2 (0.3 mg/kg) | SMMALA | 5000 | 151.6 | 866.8 | 5.7 |
| R1c mAb opt2 (3 mg/kg) | SMMALA | 5000 | 162.9 | 828.8 | 5.1 |
| R1c mAb opt2 (10 mg/kg) | SMMALA | 5000 | 173.4 | 551.0 | 3.2 |
| R1c mAb opt1 (10 mg/kg) | RWMH | 50,000 | 142.4 | 267.2 | 1.9 |
ESS effective sample size